Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Miniaturized System for Screening of Primary Cells based on Droplet Microarray

Project description

Cell cultures in tiny droplets could have big impact on therapeutics

High-throughput cell screening is integral to medical and pharmaceutical research and clinical medicine, enabling scientists to evaluate thousands of chemical compounds that interact with biological target molecules. However, current methods have limitations, including the high costs and scarcity of cell samples and the tremendous volume of microtitre plates and reagents that are required. The German SME AQUARRAY has developed patented droplet microarray technology for cell cultivation, ultrahigh-throughput screening, and a biochemical assay that enables downscaling of the experiments and significant savings in consumables. Microdroplets formed spontaneously serve as individual micro-reservoirs for culturing cells. The EU-funded Droplet Microarray project supports development of a business and commercialisation plan to bring the technology to market, benefiting basic and applied research, drug discovery and personalised medicine.

Objective

Current cell screening systems based on microtiter plates are mainly used to perform drug discovery experiments. However, performing a larger number of therapeutic tests on patient derived (primary) cells is yet impossible due to the high consumption of reagents and cells when using microplates. In the clinical context, personalized drug screenings for optimal medical treatment are not possible due to the scarcity of precious primary cells. In pre-clinical drug discovery, the extremely high cost of primary cells limits the innovation potential as researchers hardly have access to screening models which are relevant for human physiology. The possibility to use scarce cell types like primary cells or stem cells therefore is the future of basic life science research, drug discovery (replacing animal models) as well as personalized medicine applications (individual precision therapies) and will have significant impact for a healthy society. Further miniaturization of current assays would inevitably allow the wide use of scarce cell types and at the same time reduce costs, increase throughput, and increase biological relevance of screening results. DMA allows researchers and clinicians to perform meaningful experiments with primary cells and circulating tumor cells – alternative technologies hardly work with low cell numbers.
EC funding Phase 2 will allow Aquarray to mass produce its offer – the DMA Cartridge and also the disruptive Cell Screening System that integrates the DMA Cartridge with a nanoliter dispenser, an incubator and a read-out apparatus. Aquarray’s disruptive business model will employ a B2B direct sales of the DMA Slides and the Screening System, and at the same time sales can be maximized through partnerships with companies selling liquid nano-dispensers such as Dispendix and Labcyte. We are expected to generate €167M revenues by 2025 capturing 9.37% of the market.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

AQUARRAY GMBH
Net EU contribution
€ 1 749 825,00
Address
HERMANN-VON-HELMHOLTZ-PLATZ 1
76344 Eggenstein-Leopoldshafen
Germany
SME
Yes
Region
Baden-Württemberg Karlsruhe Karlsruhe, Landkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 499 750,00